OR WAIT null SECS
Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
There are several live microbiota therapeutics in development, including RBX2660.
The race for the first approved live microbiota therapeutic for patients with recurrent Clostridioides difficile infections (rCDI) will be competitive with several companies preparing treatments.
RBX2660 could be toward the top of the potential treatments approved by the US Food and Drug Administration (FDA).
The latest data on the treatment was presented during the 2022 Digestive Disease Week Annual Meeting in San Diego.
In the study, investigators found RBX2660 was superior to placebo in treatment success across all subgroups in reducing rCDI in a broad patient population.
The study, dubbed the PUNCH 2 trial, in the latest to show the potential live microbiota therapeutics have in treating this patient population.
In an interview with HCPLive®, Paul Feuerstadt, MD, Assistant Clinical Professor of Medicine, Yale School of Medicine, explained how promising RBX2660 is.
Feuerstadt also discussed the need to develop treatments that reduce the risk of recurrence of C difficile, mainly because a lot of the measures put in place, even prior to the COVID-19 pandemic, in hospitals, such as enhanced sanitation and distancing, has put a dent in the rate of hospital-acquired infections.